Germ line and somatic mutations of BRAF V599E in ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 17, Issue 4, 2007, Pages 794-797

  Ueda, M ^a   Toji, E ^a   Noda, S ^a  

^a Osaka Cancer Prevention and Detection Center   (Japan)

Author keywords

BRAF V599E; Mutational analysis; Ovarian tumorigenesis

Indexed keywords

B RAF KINASE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLEAR CELL CARCINOMA; DISEASE COURSE; ENDOMETRIOID CARCINOMA; FEMALE; GENE FUNCTION; GERM LINE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; SOMATIC MUTATION;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOMA, SEROUS; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 34447308265     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00853.x     Document Type: Article

References (22)

1. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001 93: 53 62.
2. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002 417: 949 54.
3. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002 418: 934.
4. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003 63: 1454 7.
5. Singer G, Oldt R 3rd., Cohen Y et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003 95: 484 6.
6. Sieben NL, Macropoulos P, Roemen GM et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004 202: 336 40.
7. Russell SE, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 2004 203: 617 9.
8. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih IeM. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004 64: 6915 8.
9. Singer G, Kurman RJ, Chang HW, Cho SK, IeM Shih. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002 160: 1223 8.
10. Cuatrecasas M, Erill N, Musulen E, Costa I, Matias-Guiu X, Prat J. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cancer 1998 82: 1088 95.
11. Singer G, Stohr R, Cope L et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005 29: 218 24.
12. Kiyozuka Y, Ito K, Nakano S et al. Antiproliferative actions of medroxy-progesterone acetate (MPA) to human ovarian cancer cell lines in vitro. Acta Obstet Gynaecol Jpn 1992 44: 137 44.
13. Tsuji Y, Suzuki T, Nishiura H, Takemura T, Isojima S. Identification of two different surface epitopes of human ovarian epithelial carcinomas by monoclonal antibodies. Cancer Res 1985 45: 2358 62.
14. Ishiwata I, Ishiwata C, Soma M, Nozawa S, Ishikawa H. Characterization of newly established human ovarian carcinoma cell line - special reference of the effects of cis-platinum on cellular proliferation and release of CA125. Gynecol Oncol 1987 26: 340 54.
15. Yamada T, Ueda M, Otsuki Y, Ueki M, Sugimoto O. Establishment and characterization of a cell line (OMC-3) originating from a human mucinous cystadenocarcinoma of the ovary. Gynecol Oncol 1991 40: 118 28.
16. Nozawa S, Tsukazaki K, Sakayori M, Jeng CH, Iizuka R. Establishment of a human ovarian clear cell carcinoma cell line (RMG-I) and its single cell cloning-with special reference to the stem cell of the tumor. Hum Cell 1988 1: 426 35.
17. Nozawa S, Yajima M, Sasaki H et al. A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II). Jpn J Cancer Res 1991 82: 854 61.
18. Ishiwata I, Ishiwata C, Soma M, Ishikawa H. Establishment of HUOCA-II, a human ovarian clear cell adenocarcinoma cell line, and its angiogenic activity. J Natl Cancer Inst 1987 78: 667 73.
19. Suzuki N, Oiwa Y, Sugano I et al. Dipyridamole enhances an anti-proliferative effect of interferon in various types of human tumor cells. Int J Cancer 1992 51: 627 33.
20. Ishiwata I, Ishiwata C, Soma M, Ishikawa H. Establishment and characterization of two human ovarian endometrioid carcinoma cell lines (with or without squamous cell component). Gynecol Oncol 1986 25: 95 107.
21. Ueda M, Gemmill RM, West J et al. Mutations of the beta- and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer 2001 85: 64 8.
22. Sato N, Tsunoda H, Nishida M et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000 60: 7052 6.